Summary
Alemtuzumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Immune Thrombocytopaenia (ITP) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Immune Thrombocytopaenia (ITP). ClinicalTrials.gov lists 2 registered trials linking Alemtuzumab to Immune Thrombocytopaenia (ITP): 2 have completed. The most advanced is Phase 4 (NCT03784898). The largest enrolment is 19 participants (NCT00749112). Registration activity spans 2008 to 2019. No published literature item is linked to Alemtuzumab and Immune Thrombocytopaenia (ITP) in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Immune Thrombocytopenia ranks 50 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Childhood ITP: spontaneous remission in 70-80% within 6 months; Adult ITP: spontaneous remission in 20-30% at 1 year without treatment; chronic ITP (>12 months) rarely resolves spontaneously.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 27.0 (trials 7.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 2 total: 0 recruiting, 0 active / not yet recruiting, 2 completed, 0 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | antibody; antibody; inhibitor |
| Data sources | DGIdb |
| Linked via biomarker / target | CD52 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03784898 | Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada 2019 | completed | Phase 4 | 13 |
| NCT00749112 | Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias 2008 | completed | PHASE2, PHASE3 | 19 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
Recorded mechanism or class: antibody; antibody; inhibitor.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CD52. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Alemtuzumab approved for Immune Thrombocytopaenia (ITP)?
Alemtuzumab has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Immune Thrombocytopaenia (ITP) would be drug repurposing rather than first-in-human development. This does not mean it is approved for Immune Thrombocytopaenia (ITP). Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Alemtuzumab in clinical trials for Immune Thrombocytopaenia (ITP)?
ClinicalTrials.gov lists 2 registered trials linking Alemtuzumab to Immune Thrombocytopaenia (ITP): 2 have completed. The most advanced is Phase 4 (NCT03784898). The largest enrolment is 19 participants (NCT00749112). Registration activity spans 2008 to 2019.
What does the evidence show for Alemtuzumab in Immune Thrombocytopaenia (ITP)?
Alemtuzumab has 2 completed registered trials for Immune Thrombocytopaenia (ITP) but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CD52. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-06. Page built 2026-10-07.